IMMUNE THROMBOCYTOPENIC PURPURA (ITP)
Clinical trials for IMMUNE THROMBOCYTOPENIC PURPURA (ITP) explained in plain language.
Never miss a new study
Get alerted when new IMMUNE THROMBOCYTOPENIC PURPURA (ITP) trials appear
Sign up with your email to follow new studies for IMMUNE THROMBOCYTOPENIC PURPURA (ITP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New shot shows promise for Long-Term control of bleeding disorder
Disease control Recruiting nowThis study tests the long-term safety of a drug called mezagitamab for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing easy bruising and bleeding. About 150 participants who were in earlier mezagitamab studies wil…
Matched conditions: IMMUNE THROMBOCYTOPENIC PURPURA (ITP)
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated May 17, 2026 04:33 UTC
-
New shot could help ITP patients avoid bleeding risks
Disease control Recruiting nowThis study tests a drug called mezagitamab for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. The drug is given as a shot under the skin for up to 6 months. The goal is to see if it can keep platel…
Matched conditions: IMMUNE THROMBOCYTOPENIC PURPURA (ITP)
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New drug hope for teens with rare bleeding disorder
Disease control Recruiting nowThis study tests an IV medicine called efgartigimod in teens aged 12 to 18 who have had immune thrombocytopenia (ITP) for over a year. ITP causes low platelet counts, leading to bruising and bleeding. The goal is to find the right dose and see if it safely raises platelet levels.…
Matched conditions: IMMUNE THROMBOCYTOPENIC PURPURA (ITP)
Phase: PHASE2, PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 08, 2026 12:00 UTC